TrialOrphanet journal of rare diseases2017

A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.

Barry J Byrne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.